The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wall, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase;
wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.

This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.

Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment of Pseudomonas infection.

According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the target antigen with an EC.sub.50 of about 10 nM or less, and/or are capable of promoting complement deposition on the target antigen with an EC.sub.50 of about 10 nM. In certain embodiments, the bispecific antigen-binding molecules of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of an infectious agent or cancer cell is desired and/or therapeutically beneficial.

The present invention relates to an immunodiagnostic kit and method for co-detection of R. solanacearum and F. oxysporum that cause bacterial wilt disease and fungal wilt disease, respectively, which are difficult to accurately diagnose due to the overlapping onset time and similar disease symptoms thereof in plants, and to a test kit for determining a pathogen of plant wilt disease in an early stage by using a semi-quantitative lateral flow immunodiagnostic technique to detect the pathogen in a plant juice. In addition, the kit and method can semi-quantitatively measure a density of a pathogen to determine a degree of infection to the plant. According to the configuration of the present invention, the kit and method can simultaneously detect R. solanacearum and F. oxysporum in a separate manner and as such, is helpful in accurately diagnosing diseases more easily within a shorter period of time than conventional observation by naked eye or microorganism separation and identification methods. Therefore, the present invention can advantageously contribute to the selection by farmers of chemicals for treatment of plant diseases.

Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.

Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.

The present invention provides a protein molecule effective for an anti-Pseudomonas aeruginosa vaccine. A protein molecule comprising PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains.

Provided herein are antibodies including antigen-binding fragments thereof that specifically recognizing Pseudomonas Psl. Also provided are methods of making and using these antibodies.

Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment of Pseudomonas infection.